Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients
Nephrology, Dialysis, Transplantation , Volume 28 - Issue 12 p. 3062- 3071
Background. The development of atherosclerosis may be enhanced by iron accumulation in macrophages. Hepcidin-25 is a key regulator of iron homeostasis, which downregulates the cellular iron exporter ferroportin. In haemodialysis (HD) patients, hepcidin-25 levels are increased. Therefore, it is conceivable that hepcidin-25 is associated with all-cause mortality and/or fatal and non-fatal cardiovascular (CV) events in this patient group. The aim of the current analysis was to study the relationship between hepcidin-25 and all-cause mortality and both fatal and non-fatal CV events in chronic HD patients. Methods. Data from 405 chronic HD patients included in the CONvective TRAnsport STudy (NCT00205556) were studied (62% men, age 63.7 ± 13.9 years [mean ± SD]). The median (range) follow-up was 3.0 (0.8-6.6) years. Hepcidin-25 was measured with mass spectrometry. The relationship between hepcidin-25 and all-cause mortality or fatal and non-fatal CV events was investigated with multivariate Cox proportional hazard models. Results. Median (interquartile range) hepcidin-25 level was 13.8 (6.6-22.5) nmol/L. During follow-up, 158 (39%) patients died from any cause and 131 (32%) had a CV event. Hepcidin-25 was associated with all-cause mortality in an unadjusted model [hazard ratio (HR) 1.14 per 10 nmol/L, 95% CI 1.03-1.26; P = 0.01], but not after adjustment for all confounders including high-sensitive C-reactive protein (HR 1.02 per 10 nmol/L, 95% CI 0.87-1.20; P = 0.80). At the same time, hepcidin-25 was significantly related to fatal and non-fatal CV events in a fully adjusted model (HR 1.24 per 10 nmol/L, 95% CI 1.05-1.46, P = 0.01). Conclusion. Hepcidin-25 was associated with fatal and nonfatal CV events, even after adjustment for inflammation. Furthermore, inflammation appears to be a significant confounder in the relation between hepcidin-25 and all-cause mortality. These findings suggest that hepcidin-25 might be a novel determinant of CV disease in chronic HD patients.
|Cardiovascular events, Haemodialysis, Hepcidin-25, Inflammation, Mortality|
|Nephrology, Dialysis, Transplantation|
|Organisation||Department of Internal Medicine|
van der Weerd, N.C, Grooteman, M.P.C, Bots, M.L, van den Dorpel, M.A, den Hoedt, C.H, Mazairac, A.H.A, … ter Wee, P.M. (2013). Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrology, Dialysis, Transplantation, 28(12), 3062–3071. doi:10.1093/ndt/gfs488